IPO Details
Below are key details about the IPO of the Company
- IPO Start Date – 09th Nov 2020
- IPO End Date – 11th Nov 2020
- IPO Price – INR 1,490 – 1,500
- IPO Lot Size – 10
- Minimum investment required – INR 15,000
English Video
Hindi Video
Business Details
Gland Pharma IPO us touted as one of the largest Pharma IPO in India. It is one of the largest Injectable companies in India. It is business to business Company and planning to remain the same in near future.
The Company has seven manufacturing units present in India.The combined production capacity of the Company is around 750 million units. Out of seven facilities four are dedicated to finished formulations and three is dedicated to API.
Below are the product categories of the Company
- Anti Malaria
- Anti-Neoplastics
- Cardiac
- Gynaecological
- Nuero/CNS
- Respiratory
- Anti-Infectives
- Gastro Intestinal
- Hormones
- Ophthal/Otologicals
- Pain/Analgesics
- Vitamins/Minerals and Nutrients
Below are the key molecules from the Company
- Heparin Sodium Injection
- Enoxaparin Sodium Injection
- Rocuronium Bromide Injection
- Daptomycin Injection
It exports the products to different continents. It has presence in North America, Europe and Australia. The Company exports products to approx 60 countries around the globe making it a global Company.
Financial Snapshot
Below are key financials of the Company for year ending 2020
- Total Income – 27,724
- Profit for year – 7,728
- PE – 31.7
IPO Subscription Status
Below is IPO Subscription status of the Company. I will be updating this section with time.
- QIB – 06.40 times
- NII – 0.51 times
- RII – 0.24 times
- Total Subscription is 02.06 times
Below is meaning of the Key terms used above
- QIB is (Institutes or Mutual Funds like HDFC AMC etc)
- NII is (People bidding for more than 2 lakhs in IPO application)
- RII is (People bidding for less than 2 lakhs)
- Employee and Others are Reserved Quota Investors.
My Opinion
The promoters of Gland Pharma are Fosun Pharma which is a Chinese Company. So it can be viewed as Multinational Company with Chinese parentage. With current political situation with China this may be one of the negatives for the Company.
Having said that Pharma as a sector is seeing traction in post Covid days and the positive sentiment will help Pharma company IPO. Quality wise Company is good as they have good reputation when it comes to US FDA.
It will be interesting to see the Subscription status and based on that you can take your call. Nifty is in bullish phase and that may also help the IPO listing.